A citation-based method for searching scientific literature

Kosuke Nakajo, Takehiro Uda, Toshiyuki Kawashima, Yuzo Terakawa, Kenichi Ishibashi, Naohiro Tsuyuguchi, Yuta Tanoue, Atsufumi Nagahama, Hiroshi Uda, Saya Koh, Tsuyoshi Sasaki, Kenji Ohata, Yonehiro Kanemura, Takeo Goto. World Neurosurg 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Use of PET Imaging in Neuro-Oncological Surgery.
Adrien Holzgreve, Nathalie L Albert, Norbert Galldiks, Bogdana Suchorska. Cancers (Basel) 2021
2
100

Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
Danielle M Burgenske, Jie Yang, Paul A Decker, Thomas M Kollmeyer, Matthew L Kosel, Ann C Mladek, Alissa A Caron, Rachael A Vaubel, Shiv K Gupta, Gaspar J Kitange,[...]. Neuro Oncol 2019
17
100


Cell Lineage-Based Stratification for Glioblastoma.
Zilai Wang, Daochun Sun, Yu-Jung Chen, Xuanhua Xie, Yufeng Shi, Viviane Tabar, Cameron W Brennan, Tejus A Bale, Chenura D Jayewickreme, Dan R Laks,[...]. Cancer Cell 2020
8
100

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.
Brian M Alexander, Sujuan Ba, Mitchel S Berger, Donald A Berry, Webster K Cavenee, Susan M Chang, Timothy F Cloughesy, Tao Jiang, Mustafa Khasraw, Wenbin Li,[...]. Clin Cancer Res 2018
60
100

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
Patrick Y Wen, Jan Drappatz, John de Groot, Michael D Prados, David A Reardon, David Schiff, Marc Chamberlain, Tom Mikkelsen, Annick Desjardins, Jaymes Holland,[...]. Neuro Oncol 2018
33
100

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Linda M Liau, Keyoumars Ashkan, David D Tran, Jian L Campian, John E Trusheim, Charles S Cobbs, Jason A Heth, Michael Salacz, Sarah Taylor, Stacy D D'Andre,[...]. J Transl Med 2018
149
100

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.
Catherine Uyttenhove, Luc Pilotte, Ivan Théate, Vincent Stroobant, Didier Colau, Nicolas Parmentier, Thierry Boon, Benoît J Van den Eynde. Nat Med 2003
100

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Giuseppe Lombardi, Gian Luca De Salvo, Alba Ariela Brandes, Marica Eoli, Roberta Rudà, Marina Faedi, Ivan Lolli, Andrea Pace, Bruno Daniele, Francesco Pasqualetti,[...]. Lancet Oncol 2019
68
100

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
E Franceschi, G Cavallo, S Lonardi, E Magrini, A Tosoni, D Grosso, L Scopece, V Blatt, B Urbini, A Pession,[...]. Br J Cancer 2007
135
100

The effect of re-operation on survival in patients with recurrent glioblastoma.
Enrico Franceschi, Marco Bartolotti, Alicia Tosoni, Stefania Bartolini, Carmelo Sturiale, Antonio Fioravanti, Eugenio Pozzati, Renato Galzio, Andrea Talacchi, Lorenzo Volpin,[...]. Anticancer Res 2015
28
100

A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?
Giuseppe Lombardi, Ahmed Idbaih, Emilie Le Rhun, Matthias Preusser, Vittorina Zagonel, Pim French. Cancers (Basel) 2020
3
100

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors.
Karisa C Schreck, Stuart A Grossman, Christine A Pratilas. Cancers (Basel) 2019
27
100

Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
A Tosoni, E Franceschi, M Ermani, R Bertorelle, L Bonaldi, V Blatt, Alba A Brandes. J Neurooncol 2008
60
100

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.
Alba A Brandes, Miguel Gil-Gil, Frank Saran, Antoine F Carpentier, Anna K Nowak, Warren Mason, Vittorina Zagonel, François Dubois, Gaetano Finocchiaro, George Fountzilas,[...]. Oncologist 2019
16
100


A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas.
Teri N Kreisl, Svetlana Kotliarova, John A Butman, Paul S Albert, Lyndon Kim, Luna Musib, Donald Thornton, Howard A Fine. Neuro Oncol 2010
74
100

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.
Quinn T Ostrom, Gino Cioffi, Haley Gittleman, Nirav Patil, Kristin Waite, Carol Kruchko, Jill S Barnholtz-Sloan. Neuro Oncol 2019
563
100

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Roger Stupp, Sophie Taillibert, Andrew Kanner, William Read, David Steinberg, Benoit Lhermitte, Steven Toms, Ahmed Idbaih, Manmeet S. Ahluwalia, Karen Fink,[...]. JAMA 2017
571
100

EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
Alba A Brandes, Roger Stupp, Peter Hau, Denis Lacombe, Thierry Gorlia, Alicia Tosoni, Renè O Mirimanoff, Johan M Kros, Martin J van den Bent. Eur J Cancer 2010
55
100

Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.gov.
Nikola Cihoric, Alexandros Tsikkinis, Giuseppe Minniti, Frank J Lagerwaard, Ulrich Herrlinger, Etienne Mathier, Ivan Soldatovic, Branislav Jeremic, Pirus Ghadjar, Olgun Elicin,[...]. Radiat Oncol 2017
54
100

The impact of socioeconomic status on access to cancer clinical trials.
K Sharrocks, J Spicer, D R Camidge, S Papa. Br J Cancer 2014
43
100

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, Joachim Peter Steinbach, Uwe Schlegel, Michael Sabel, Peter Hau, Rolf-Dieter Kortmann, Dietmar Krex, Oliver Grauer,[...]. Lancet 2019
136
100

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Deborah T Blumenthal, Thierry Gorlia, Mark R Gilbert, Michelle M Kim, L Burt Nabors, Warren P Mason, Monika E Hegi, Peixin Zhang, Vassilis Golfinopoulos, James R Perry,[...]. Neuro Oncol 2017
48
100

The clinical and prognostic role of ALK in glioblastoma.
Enrico Franceschi, Dario De Biase, Vincenzo Di Nunno, Annalisa Pession, Alicia Tosoni, Lidia Gatto, Giovanni Tallini, Michela Visani, Raffaele Lodi, Stefania Bartolini,[...]. Pathol Res Pract 2021
2
100

Predictive markers of immune response in glioblastoma: hopes and facts.
Vincenzo Di Nunno, Enrico Franceschi, Lidia Gatto, Stefania Bartolini, Alba Ariela Brandes. Future Oncol 2020
3
100

Bayesian adaptive randomized trial design for patients with recurrent glioblastoma.
Lorenzo Trippa, Eudocia Q Lee, Patrick Y Wen, Tracy T Batchelor, Timothy Cloughesy, Giovanni Parmigiani, Brian M Alexander. J Clin Oncol 2012
59
100

MET in glioma: signaling pathways and targeted therapies.
Fangling Cheng, Dongsheng Guo. J Exp Clin Cancer Res 2019
34
100

Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma.
Wenting Wu, Kathleen R Lamborn, Jan C Buckner, Paul J Novotny, Susan M Chang, Judith R O'Fallon, Kurt A Jaeckle, Michael D Prados. Neuro Oncol 2010
57
100

Chimeric antigen receptor macrophage for glioblastoma immunotherapy: the way forward.
Lidia Gatto, Vincenzo Di Nunno, Enrico Franceschi, Alba Ariela Brandes. Immunotherapy 2021
1
100

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.
Timothy F Cloughesy, Aaron Y Mochizuki, Joey R Orpilla, Willy Hugo, Alexander H Lee, Tom B Davidson, Anthony C Wang, Benjamin M Ellingson, Julie A Rytlewski, Catherine M Sanders,[...]. Nat Med 2019
334
100

Post progression survival in glioblastoma: where are we?
Enrico Franceschi, Mario Ermani, Stefania Bartolini, Marco Bartolotti, Rosalba Poggi, Giovanni Tallini, Gianluca Marucci, Antonio Fioravanti, Alicia Tosoni, Raffaele Agati,[...]. J Neurooncol 2015
7
100

To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs.
Alyssa M Vanderbeek, Steffen Ventz, Rifaquat Rahman, Geoffrey Fell, Timothy F Cloughesy, Patrick Y Wen, Lorenzo Trippa, Brian M Alexander. Neuro Oncol 2019
2
100

Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
Nicholas Butowski, Susan M Chang, Kathleen R Lamborn, Mei-Yin Polley, Russell Pieper, Joseph F Costello, Scott Vandenberg, Rupa Parvataneni, Angelina Nicole, Patricia K Sneed,[...]. Neuro Oncol 2011
51
100

DNX-2401: an investigational drug for the treatment of recurrent glioblastoma.
Brandon Philbrick, David C Adamson. Expert Opin Investig Drugs 2019
11
100

The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?
Alyssa M Vanderbeek, Rifaquat Rahman, Geoffrey Fell, Steffen Ventz, Tianqi Chen, Robert Redd, Giovanni Parmigiani, Timothy F Cloughesy, Patrick Y Wen, Lorenzo Trippa,[...]. Neuro Oncol 2018
37
100

Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?
Enrico Franceschi, Giuseppe Lamberti, Alexandro Paccapelo, Monica Di Battista, Giovenzio Genestreti, Santino Minichillo, Antonella Mura, Stefania Bartolini, Raffaele Agati, Alba A Brandes. J Neurooncol 2018
9
100

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
David A Reardon, Annick Desjardins, Katherine B Peters, Sridharan Gururangan, John H Sampson, Roger E McLendon, James E Herndon, Anuradha Bulusu, Stevie Threatt, Allan H Friedman,[...]. J Neurooncol 2012
100
100

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Martin J van den Bent, Alba A Brandes, Roy Rampling, Mathilde C M Kouwenhoven, Johan M Kros, Antoine F Carpentier, Paul M Clement, Marc Frenay, Mario Campone, Jean-Francois Baurain,[...]. J Clin Oncol 2009
374
100


Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma.
Brian M Alexander, Lorenzo Trippa, Sarah Gaffey, Isabel C Arrillaga-Romany, Eudocia Q Lee, Mikael L Rinne, Manmeet S Ahluwalia, Howard Colman, Geoffrey Fell, Evanthia Galanis,[...]. JCO Precis Oncol 2019
12
100

Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement.
Ken Chang, Andrew L Beers, Harrison X Bai, James M Brown, K Ina Ly, Xuejun Li, Joeky T Senders, Vasileios K Kavouridis, Alessandro Boaro, Chang Su,[...]. Neuro Oncol 2019
43
100

Current Development of Glioblastoma Therapeutic Agents.
Zilai Wang, Norton P Peet, Pin Zhang, Yuwei Jiang, Lijun Rong. Mol Cancer Ther 2021
1
100

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study.
Alba A Brandes, Gaetano Finocchiaro, Vittorina Zagonel, Michele Reni, Alessandra Fabi, Claudia Caserta, Alicia Tosoni, Marica Eoli, Giuseppe Lombardi, Matteo Clavarezza,[...]. Oncotarget 2017
5
100

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.
Michael Weller, Martin van den Bent, Matthias Preusser, Emilie Le Rhun, Jörg C Tonn, Giuseppe Minniti, Martin Bendszus, Carmen Balana, Olivier Chinot, Linda Dirven,[...]. Nat Rev Clin Oncol 2021
51
100

Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma.
Benjamin M Ellingson, John Sampson, Achal Singh Achrol, Manish K Aghi, Krystof Bankiewicz, Chencai Wang, Martin Bexon, Steven Brem, Andrew Brenner, Sajeel Chowdhary,[...]. Clin Cancer Res 2021
1
100

Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
Juan Manuel Sepúlveda-Sánchez, María Ángeles Vaz, Carmen Balañá, Miguel Gil-Gil, Gaspar Reynés, Óscar Gallego, María Martínez-García, Elena Vicente, María Quindós, Raquel Luque,[...]. Neuro Oncol 2017
43
100

Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study.
Andrew Yu, Nadia Faiq, Stacey Green, Albert Lai, Richard Green, Jethro Hu, Timothy F Cloughesy, Ingo Mellinghoff, P Leia Nghiemphu. J Neurooncol 2017
14
100

Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.
Lijie Zhai, Erik Ladomersky, Kristen L Lauing, Meijing Wu, Matthew Genet, Galina Gritsina, Balázs Győrffy, Priscilla K Brastianos, David C Binder, Jeffrey A Sosman,[...]. Clin Cancer Res 2017
74
100

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.